# Illumina, Inc.: overview

ILMN · Nasdaq · CIK 1110803 · [Technology](/sectors/technology.md) · fiscal year ends Jan 3

Pages: [Overview](/companies/ilmn.md) · [Financials](/companies/ilmn/financials.md) · [Filings](/companies/ilmn/filings.md) · [Insiders](/companies/ilmn/insiders.md)

Latest reported revenue: [$1.16bn](/filings/0001110803-26-000160.md) for Q2 FY2026, three months to 2026-06-28, from the 10-Q filed Jul 31, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001110803-26-000160).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,080](/filings/0001110803-25-000073.md) | [1,104 d](/filings/0001110803-26-000024.md) | [1,041](/filings/0001110803-26-000092.md) | [1,059](/filings/0001110803-26-000160.md) | [1,084](/filings/0001110803-25-000073.md) | [1,159 d](/filings/0001110803-26-000024.md) | [1,091](/filings/0001110803-26-000092.md) | [1,159](/filings/0001110803-26-000160.md) |
| Gross margin | % | [69.0%](/filings/0001110803-25-000073.md) | [65.9% d](/filings/0001110803-26-000024.md) | [65.6%](/filings/0001110803-26-000092.md) | [65.6%](/filings/0001110803-26-000160.md) | [67.6%](/filings/0001110803-25-000073.md) | [65.5% d](/filings/0001110803-26-000024.md) | [66.1%](/filings/0001110803-26-000092.md) | [66.4%](/filings/0001110803-26-000160.md) |
| Operating margin | % | [68.6%](/filings/0001110803-25-000073.md) | [15.9% d](/filings/0001110803-26-000024.md) | [15.8%](/filings/0001110803-26-000092.md) | [20.2%](/filings/0001110803-26-000160.md) | [20.9%](/filings/0001110803-25-000073.md) | [17.3% d](/filings/0001110803-26-000024.md) | [19.2%](/filings/0001110803-26-000092.md) | [21.1%](/filings/0001110803-26-000160.md) |
| Net margin | % | [65.3%](/filings/0001110803-25-000073.md) | [16.8% d](/filings/0001110803-25-000073.md) | [12.6%](/filings/0001110803-26-000160.md) | [22.2%](/filings/0001110803-26-000160.md) | [13.8%](/filings/0001110803-26-000160.md) | [28.8% d](/filings/0001110803-26-000160.md) | [12.3%](/filings/0001110803-26-000160.md) | [17.9%](/filings/0001110803-26-000160.md) |
| Diluted EPS | $ per share | [4.42](/filings/0001110803-25-000073.md) | not reported | [0.82](/filings/0001110803-26-000092.md) | [1.49](/filings/0001110803-26-000160.md) | [0.98](/filings/0001110803-25-000073.md) | not reported | [0.87](/filings/0001110803-26-000092.md) | [1.35](/filings/0001110803-26-000160.md) |
| Free cash flow | $m | [284 d](/filings/0001110803-25-000073.md) | [335 d](/filings/0001110803-26-000024.md) | [208](/filings/0001110803-26-000092.md) | [204 d](/filings/0001110803-26-000160.md) | [253 d](/filings/0001110803-25-000073.md) | [266 d](/filings/0001110803-26-000024.md) | [251](/filings/0001110803-26-000092.md) | [161 d](/filings/0001110803-26-000160.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2022-01-02) | FY2022 (2023-01-01) | FY2023 (2023-12-31) | FY2024 (2024-12-29) | FY2025 (2025-12-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,526](/filings/0001110803-24-000010.md) | [4,584](/filings/0001110803-25-000019.md) | [4,504](/filings/0001110803-26-000024.md) | [4,372](/filings/0001110803-26-000024.md) | [4,343](/filings/0001110803-26-000024.md) |
| Gross margin | % | [69.7%](/filings/0001110803-24-000010.md) | [64.8%](/filings/0001110803-25-000019.md) | [60.9%](/filings/0001110803-26-000024.md) | [65.4%](/filings/0001110803-26-000024.md) | [66.1%](/filings/0001110803-26-000024.md) |
| Operating margin | % | [(2.7%)](/filings/0001110803-24-000010.md) | [(91.2%)](/filings/0001110803-25-000019.md) | [(23.7%)](/filings/0001110803-26-000024.md) | [(19.1%)](/filings/0001110803-26-000024.md) | [18.6%](/filings/0001110803-26-000024.md) |
| Net margin | % | [16.8%](/filings/0001110803-24-000010.md) | [(96.1%)](/filings/0001110803-25-000019.md) | [(25.8%)](/filings/0001110803-26-000024.md) | [(28.0%)](/filings/0001110803-26-000024.md) | [19.6%](/filings/0001110803-26-000024.md) |
| Diluted EPS | $ per share | [5.04](/filings/0001110803-24-000010.md) | [(28.00)](/filings/0001110803-25-000019.md) | [(7.34)](/filings/0001110803-26-000024.md) | [(7.69)](/filings/0001110803-26-000024.md) | [5.45](/filings/0001110803-26-000024.md) |
| Free cash flow | $m | [337](/filings/0001110803-24-000010.md) | [106](/filings/0001110803-25-000019.md) | [283](/filings/0001110803-26-000024.md) | [709](/filings/0001110803-26-000024.md) | [931](/filings/0001110803-26-000024.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ilmn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $3.37bn | 19,191,398 |  | Added +167,808 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $2.71bn | 15,425,298 |  | Reduced −124,662 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.17bn | 6,627,157 |  | Reduced −196,497 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.16bn | 6,587,534 |  | Reduced −7,302 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.14bn | 6,507,288 |  | Added +77,944 |
| [WCM INVESTMENT MANAGEMENT, LLC](/funds/1061186.md) | 2026-06-30 | $1.12bn | 6,206,701 |  | Added +283,528 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $795.4m | 4,523,417 |  | Added +2,976,556 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $623.2m | 3,544,465 |  | Reduced −436,615 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $618.0m | 3,514,649 |  | Added +1,447,350 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $516.7m | 2,946,669 |  | Reduced −104,610 |

## Recent filings

[All 2,905 filings](/companies/ilmn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:07 ET | [8-K](/filings/0001110803-26-000202.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001110803-26-000202 |
| 2026-10-13 | 16:48 ET | [8-K](/filings/0001110803-26-000195.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001110803-26-000195 |
| 2026-08-17 | 16:02 ET | [8-K](/filings/0001193125-26-354010.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-354010 |
| 2026-08-13 | 16:18 ET | [8-K](/filings/0000950157-26-000888.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0000950157-26-000888 |
| 2026-08-12 | 08:00 ET | [8-K](/filings/0001193125-26-345802.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-345802 |
| 2026-08-07 | 16:25 ET | [8-K](/filings/0001110803-26-000168.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001110803-26-000168 |
| 2026-07-31 | 17:05 ET | [10-Q](/filings/0001110803-26-000160.md) | Quarterly report, period 2026-06-28 | 0001110803-26-000160 |
| 2026-07-30 | 16:07 ET | [8-K](/filings/0001110803-26-000155.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001110803-26-000155 |
| 2026-06-23 | 09:08 ET | [8-K](/filings/0001110803-26-000138.md) | 5.02 Departure or appointment of officers or directors | 0001110803-26-000138 |
| 2026-05-26 | 17:28 ET | [8-K](/filings/0001110803-26-000124.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001110803-26-000124 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 28, 2025](/filings/0001110803-26-000024.md), filed Feb 12, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-28, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/51d18f62-d896-4384-9d45-7a51bbf89c64)

## About the filer

- CIK: 1110803
- Tickers: ILMN
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:03 ET. No prices; not investment advice.